Impact of the Placebo Effect on the Effects of Trancranial Direct Current Stimulation in Fibromyalgia
Key facts
- Who runs it
- Hospital de Clinicas de Porto Alegre
- Where
- Brazil1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 100 people enrolled
- Started
- 5 Mar 2024
- Ended
- 31 Jan 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- s-Tdcs
- Record updated
- 12 January 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Women aged 18 to 65 years; who can read and write, with a confirmed diagnosis of FM according to the American College of Rheumatology criteria (2010-2016). Pain score equal to or greater than six on the Numerical Pain Scale (NPS 0-10) on most days of the last 3 months
Who cannot take part
- Residing outside the greater Porto Alegre area and pregnancy. Contraindications to TMS and tDCS: metallic implant in the brain; medical devices implanted in the brain, cardiac pacemakers; cochlear implant; history of alcohol or drug abuse in the last 6 months; neurological pathologies; hx of head trauma or neurosurgery; decompensated systemic diseases and chronic inflammatory diseases (lupus, rheumatoid arthritis, Reiter's syndrome); uncompensated hypothyroidism; personal history of cancer, past or undergoing treatment
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Fibromyalgia (FM) is a syndrome characterized by generalized musculoskeletal pain, fatigue, non-restorative sleep, cognitive alterations, depressive and neurovegetative symptoms. Conventional pharmacological therapies are known to produce responses with little clinical impact in more than 50% of patients. Functional alterations of the motor cortex and its connections with subcortical structures have also been demonstrated in FM. Based on the above, the objective of this research is to identify subgroups of patients with greater potential for response to treatment with a view to advancing diagnosis and treatment. In this study, the therapeutic target will be transcranial direct current stimulation (tDCS) according to the potential of responsiveness to the placebo effect, with the precise location of the stimulation area by a neuronavigation system, with the objective of counter-regulating the processes dysfunctional factors responsible for triggering and maintaining FM symptoms. Therefore, this clinical trial aims to compare the effectiveness of anodal tDCS applied to the primary motor cortex (M1) compared to sham tDCS in FM, according to susceptibility to the placebo effect and serum endorphin levels.
The 2 groups in the trial
- Respondres placebo effectPlacebo, for comparison
Braço: Comparador de placebo: responde ao efeito placebo Intervenção: 'Estimulação Transcraniana por Corrente Contínua - tDCS Os pacientes receberão tratamento de estimulação tDCS córtex motor primário (M1). De acordo com o sistema 10-20 EEG, o ânodo será colocado no F3 esquerdo e o cátodo no FP2 direito. A estimulação placebo utiliza uma corrente de 2 miliamperes durante os primeiros minutos, nos 10 min e nos 19 minutos.
Treatment: s-Tdcs
- No Respondres placebo effectExisting treatment, for comparison
Braço: Comparador de placebo: responde ao efeito placebo Intervenção: 'Estimulação Transcraniana por Corrente Contínua - tDCS Os pacientes receberão tratamento de estimulação tDCS córtex motor primário (M1).De acordo com o sistema 10-20 EEG, o ânodo será colocado no F3 esquerdo e o cátodo no FP2 direitol. A estimulação placebo utiliza uma corrente de 2 miliamperes durante os primeiros minutos, nos 10 min e nos 19 minutos
Treatment: s-Tdcs
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Impact of the Placebo Effect on the Effects of Trancranial Direct Current Stimulation in Fibromyalgia:A Randomized Clinical Trial
- Record updated
- 12 January 2026